Analysis of influencing factors affecting the efficacy of Shenfukang capsule in the treatment of chronic kidney disease and construction of prediction model

TANG Li; QIN Mengyuan; YANG Yufang; ZOU Xiaoqin; LIANG Zhiwei; ZHONG Xiaobin

doi:10.6039/j.issn.1001-0408.2026.13.14

您当前的位置：

首页 >

文章列表页 >

Analysis of influencing factors affecting the efficacy of Shenfukang capsule in the treatment of chronic kidney disease and construction of prediction model

更新时间：2026-07-10

- Analysis of influencing factors affecting the efficacy of Shenfukang capsule in the treatment of chronic kidney disease and construction of prediction model
- ZHONGGUO YAOFANG Vol. 37, Issue 13, Pages: 1740-1745(2026)
- 作者机构：
  
  1.广西医科大学附属肿瘤医院药学部，南宁　530012
  2.广西医科大学第一附属医院药学部，南宁　530021
  3.广西医科大学第一附属医院科研部，南宁　530021
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.13.14
  CLC： R692.5;R285.6
- Received：10 February 2026，
  
  Revised：2026-06-04，
  
  Accepted：06 June 2026，
  
  Published：15 July 2026
- 稿件说明：
移动端阅览
唐莉,秦梦圆,杨玉芳,等.肾福康胶囊治疗慢性肾脏病疗效的影响因素分析及预测模型建立[J].中国药房,2026,37(13):1740-1745.

TANG Li,QIN Mengyuan,YANG Yufang,et al.Analysis of influencing factors affecting the efficacy of Shenfukang capsule in the treatment of chronic kidney disease and construction of prediction model[J].ZHONGGUO YAOFANG,2026,37(13):1740-1745.
唐莉,秦梦圆,杨玉芳,等.肾福康胶囊治疗慢性肾脏病疗效的影响因素分析及预测模型建立[J].中国药房,2026,37(13):1740-1745. DOI： 10.6039/j.issn.1001-0408.2026.13.14.

TANG Li,QIN Mengyuan,YANG Yufang,et al.Analysis of influencing factors affecting the efficacy of Shenfukang capsule in the treatment of chronic kidney disease and construction of prediction model[J].ZHONGGUO YAOFANG,2026,37(13):1740-1745. DOI： 10.6039/j.issn.1001-0408.2026.13.14.

摘要

目的

探索肾福康胶囊治疗慢性肾脏病（CKD）疗效的影响因素，建立预测肾福康胶囊疗效的列线图预测模型。

方法

选取2019年7月至2022年8月在广西医科大学第一附属医院住院并接受肾福康胶囊治疗的CKD患者为研究对象，从医院电子病历系统中收集患者临床资料，根据疗效结果分为有效组和无效组。采用Lasso-Logistic多因素回归分析筛选肾福康胶囊疗效的影响因素；以肾福康胶囊治疗有效为预测结局，以筛选获得的影响因素为预测变量，应用R软件构建列线图预测模型。将所有患者随机分为训练集与验证集，采用受试者操作特征曲线、校准曲线、临床决策曲线分别评价模型的区分度、校准度及临床净收益。

结果

Lasso-Logistic回归分析结果显示，合并糖尿病，血尿素氮、甘油三酯、血磷水平降低，凝血酶原时间延长，载脂蛋白AⅠ水平升高是肾福康胶囊治疗CKD疗效降低的影响因素。列线图预测模型评价结果显示，训练集和验证集的曲线下面积分别为0.745、0.797，二者数值接近且均高于0.70，表明该模型预测性能稳定；两组数据集的校准曲线拟合度较好，表明该模型校准性能良好；临床决策曲线位于两条极端参考线之上，表明该模型有较高的临床净收益。

结论

糖尿病、血尿素氮、甘油三酯、载脂蛋白AⅠ、血磷、凝血酶原时间是肾福康胶囊治疗CKD疗效的影响因素。本研究所建立的列线图预测模型可为临床合理应用肾福康胶囊以及提高其治疗CKD的疗效提供依据。

Abstract

OBJECTIVE

To explore the influencing factors of Shenfukang capsule in the treatment of chronic kidney disease （CKD） and construct a nomogram prediction model for evaluating its therapeutic efficacy.

METHODS

CKD patients who were hospitalized from July 2019 to August 2022 in the First Affiliated Hospital of Guangxi Medical University and treated with Shenfukang capsule were selected as study subjects. Clinical data of the patients were collected from the hospital’s electronic medical record system， and they were divided into an effective group and an ineffective group based on treatment outcomes. Lasso-Logistic multivariate regression analysis was used to screen the influencing factors of the efficacy of Shenfukang capsule. Using the effectiveness of Shenfukang capsule treatment as the prediction outcome and the screened influencing factors as predictor variables， a nomogram prediction model was constructed using R software. All patients were randomly divided into a training cohort and a validation cohort. The discriminative ability， calibration， and clinical net benefit of the model were evaluated using the receiver operating characteristic （ROC） curve， calibration curve， and decision curve analysis， respectively.

RESULTS

Lasso-Logistic regression analysis revealed that concurrent diabetes mellitus， decreased levels of blood urea nitrogen， triglycerides， and serum phosphorus， as well as prolonged prothrombin time and elevated apolipoprotein AⅠ levels， were influencing factors for reduced efficacy of Shenfukang capsule in CKD treatment. The evaluation results of the nomogram prediction model showed that the area under curve values were 0.745 and 0.797 in the training and validation cohorts， respectively， which were close and both exceeded 0.70， indicating stable predictive performance. The calibration curves demonstrated good agreement in both datasets， suggesting satisfactory calibration performance. The clinical decision curves were positioned above the two extreme reference lines， indicating high clinical benefit of the model.

CONCLUSIONS

Diabetes mellitus， blood urea nitrogen， triglycerides， apolipoprotein AⅠ， serum phosphorus， and prothrombin time were factors associated with the efficacy of Shenfukang capsule in CKD patients. The nomogram prediction model established in this study may provide a basis for rational clinical application of Shenfukang capsule and for improving its therapeutic efficacy in CKD.

关键词

Keywords

references

Yan M T ， Chao C T ， Lin S H . Chronic kidney disease：strategies to retard progression [J ] . IJMS ， 2021 ， 22 （ 18 ）： 10084 .

白雪莲，张佳宜，项国梁，等 . 中国成人慢性肾脏病患病率的meta分析 [J ] . 中国医药科学， 2022 ， 12 （ 9 ）： 49 - 53 .

Kidney Disease ： Improving Global Outcomes KDIGO CKD Work Group . KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease [J ] . Kidney Int ， 2024 ， 105 （ 4S ）： S117 - S314 .

Pavlović N ， Križanac M ， Kumrić M ， et al . Mitochondrial dysfunction：the silent catalyst of kidney disease progression [J ] . Cells ， 2025 ， 14 （ 11 ）： 794 .

Tinti F ， Lai S ， Noce A ， et al . Chronic kidney disease as a systemic inflammatory syndrome：update on mechanisms involved and potential treatment [J ] . Life （Basel）， 2021 ， 11 （ 5 ）： 419 .

Zeng X ， Cai G Z ， Liang T L ， et al . Rhubarb and Astragalus capsule attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction by alleviating apoptosis through regulating transforming growth factor beta 1 （TGF-β 1 ）/p38 mitogen-activated protein kinases （p38 MAPK） pathway [J ] . Med Sci Monit ， 2020 ， 26 ： e920720 .

范颖，姜开运，张红梅 . 中药药对配方理论及应用 [M ] . 沈阳：辽宁科学技术出版社， 2015 ： 56 - 57 .

Qin M Y ， Huang S Q ， Zou X Q ， et al . Drug-containing serum of Rhubarb-Astragalus capsule inhibits the epithelial-mesenchymal transformation of HK-2 by downregulating TGF-β 1 /p38MAPK/Smad2/3 pathway [J ] . J Ethnopharmacol ， 2021 ， 280 ： 114414 .

蔡果珍，钟小斌，杨玉芳，等 . 肾福康胶囊治疗肾功能不全的临床研究 [J ] . 中国药房， 2017 ， 28 （ 14 ）： 1934 - 1937 .

Mei Z W ， Chen J ， Chen P P ， et al . A nomogram to predict hyperkalemia in patients with hemodialysis：a retrospective cohort study [J ] . BMC Nephrol ， 2022 ， 23 （ 1 ）： 351 .

Yang L Y ， Niu H Y ， Zhang T ， et al . A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia [J ] . Ann Hematol ， 2024 ， 103 （ 6 ）： 1877 - 1885 .

郑筱萸 . 中药新药临床研究指导原则：试行 [M ] . 北京：中国医药科技出版社， 2002 ： 163 - 167 .

Hassanzad M ， Hajian-Tilaki K . Methods of determining optimal cut-point of diagnostic biomarkers with application of clinical data in ROC analysis：an update review [J ] . BMC Med Res Methodol ， 2024 ， 24 （ 1 ）： 84 .

Cheng W L ， Markus C ， Lim C Y ， et al . Calibration practices in clinical mass spectrometry：review and recommendations [J ] . Ann Lab Med ， 2023 ， 43 （ 1 ）： 5 - 18 .

Vickers A J ， Holland F . Decision curve analysis to evaluate the clinical benefit of prediction models [J ] . Spine J ， 2021 ， 21 （ 10 ）： 1643 - 1648 .

《延缓慢性肾脏病进展临床管理指南（2025年版）》专家组 . 延缓慢性肾脏病进展临床管理指南：2025年版 [J ] . 中华肾脏病杂志， 2025 ， 41 （ 6 ）： 455 - 488 .

Hartjes E D ， Lim Y J ， Velenosi T J ， et al . The impact of progressive chronic kidney disease on hepatic drug metabolism [J ] . Drug Metab Dispos ， 2025 ， 53 （ 6 ）： 100085 .

Butrovich M A ， Tang W F ， Boulton D W ， et al . Use of physiologically based pharmacokinetic modeling to evaluate the impact of chronic kidney disease on CYP3A4-mediated metabolism of saxagliptin [J ] . J Clin Pharmacol ， 2022 ， 62 （ 8 ）： 1018 - 1029 .

冯素香，王蒙蒙，吴兆宇，等 . 大黄5种蒽醌类成分在大鼠肝微粒体中的代谢及酶促反应动力学 [J ] . 暨南大学学报（自然科学与医学版）， 2015 ， 36 （ 5 ）： 383 - 391 .

段丽娜，卢艳 . 慢性肾衰竭患者血清PTH、ALB、ALP和钙磷乘积与继发SHPT的关系分析 [J ] . 临床研究， 2025 ， 33 （ 11 ）： 16 - 19 .

Ramos P ， Larson B ， Ashrafzadeh-Kian S ， et al . Intact fibroblast growth factor 23 concentrations in hypophosphatemic disorders [J ] . Endocr Pract ， 2023 ， 29 （ 3 ）： 193 - 198 .

Qu Z Z ， Kong X N ， Xv J ， et al . Enhance uric acid-lowering activity of Astragalus membranaceus via gut microbiota biotransformation：correlation of chemical composition w ith efficacy [J ] . Biomed Chromatogr ， 2026 ， 40 （ 6 ）： e70464 .

Wu I W ， Liao Y C ， Tsai T H ， et al . Machine-learning assisted discovery unveils novel interplay between gut microbiota and host metabolic disturbance in diabetic kidney disease [J ] . Gut Microbes ， 2025 ， 17 （ 1 ）： 2473506 .

Secondulfo C ， Izzo C ， Vecchione N ， et al . Apolipoproteins in chronic kidney disease and kidney transplant：a long unfinished story [J ] . Int J Mol Sci ， 2025 ， 26 （ 19 ）： 9664 .

He B H ， Yang Q . Recent development of LDL-based nanoparticles for cancer therapy [J ] . Pharmaceuticals （Basel）， 2022 ， 16 （ 1 ）： 18 .

李建平，朱德礼，马贞，等 . 丹芪益肾方对糖尿病肾病患者临床疗效及肾保护作用机制研究 [J ] . 广州中医药大学学报， 2025 ， 42 （ 2 ）： 350 - 357 .

Kin S ， Oe Y ， Obara T ， et al . Nicotinamide attenuates complement and coagulation pathways and resultant renal fibrosis [J ] . FASEB J ， 2025 ， 39 （ 23 ）： e71263 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of risk factors for serum digoxin concentration exceeding the warning threshold and construction of prediction model

Analysis of factors influencing the achievement of target vancomycin plasma concentration and construction of a predictive model in patients from high-altitude regions： a single-center retrospective study

Mechanism of Shenfukang capsule in ameliorating renal interstitial fibrosis by regulating cellular crosstalk via the STAT3/YAP pathway

Study on the mechanism of cordycepin inhibiting ferroptosis via the Nrf2/HO-1 pathway to delay the transformation from AKI to CKD

Analysis of influencing factors for immune-related endocrine toxicity induced by sintilimab

Related Author

QIU Sujun

CAI Yimei

LIU Jinyong

WANG Hongshan

WANG Yafeng

WU Xue

XU Guiqin

HUAN Zhilan

Related Institution

Dept. of Pharmacy， Nansha Branch， Guangzhou First People’s Hospital

Dept. of Outpatient， Nansha Branch， Guangzhou First People’s Hospital

Dept. of Infection Management， Nansha Branch， Guangzhou First People’s Hospital

Dept. of Pharmacy， Qinghai Provincial People’s Hospital

Dept. of Clinical Pharmacy， Guangxi Medical University Cancer Hospital

⁰